Skip to content

H.R. 679 · 119th Congress (2025–2027)

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.

In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.

The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 679’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Diana Harshbarger (R-TN-1)
Cosponsors
18 cosponsors

14 original · 4 later

18 R

  1. Rep. Brian Babin (R-TX-36)· Original · Jan 23, 2025
  2. Rep. Mike Bost (R-IL-12)· Original · Jan 23, 2025
  3. Rep. Andy Biggs (R-AZ-5)· Original · Jan 23, 2025
  4. Rep. James R. Baird (R-IN-4)· Original · Jan 23, 2025
  5. Rep. Randy Feenstra (R-IA-4)· Original · Jan 23, 2025
  6. Rep. Michael Guest (R-MS-3)· Original · Jan 23, 2025
  7. Rep. Clay Higgins (R-LA-3)· Original · Jan 23, 2025
  8. Rep. Kevin Hern (R-OK-1)· Original · Jan 23, 2025
  9. Rep. John R. Moolenaar (R-MI-2)· Original · Jan 23, 2025
  10. Rep. Mary E. Miller (R-IL-15)· Original · Jan 23, 2025
  11. Rep. Gary J. Palmer (R-AL-6)· Original · Jan 23, 2025
  12. Rep. Daniel Webster (R-FL-11)· Original · Jan 23, 2025
  13. Rep. Randy K. Weber, Sr. (R-TX-14)· Original · Jan 23, 2025
  14. Rep. Rudy Yakym III (R-IN-2)· Original · Jan 23, 2025
  15. Rep. Andy Harris (R-MD-1)· Later · Jan 28, 2025
  16. Rep. Keith Self (R-TX-3)· Later · Feb 4, 2025
  17. Rep. Sheri Biggs (R-SC-3)· Later · Mar 31, 2025
  18. Rep. Mark B. Messmer (R-IN-8)· Later · Feb 4, 2026
Policy area
Health
Subjects
  • Abortion
  • Drug safety, medical device, and laboratory regulation
  • Drug therapy
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Jan 23, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (1)
  1. To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

    Official title, Display title · Introduced in House